Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an incretin hormone released from intestinal L-cells in response to nutrient intake, and it acts on the GLP-1 receptor, a class B G-protein-coupled receptor expressed in pancreatic islet cells and in several other tissues including regions of the central nervous system.
Native GLP-1 has a very short half-life in circulation because it is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4). The design problem that GLP-1 analogues address is therefore one of stability: how to retain receptor agonism while resisting enzymatic degradation and renal clearance.
Structural modifications
Semaglutide is a modified version of the native GLP-1 sequence. Three features are commonly described in the medicinal chemistry literature:
- Substitution at position 8, which reduces susceptibility to DPP-4 cleavage.
- A fatty acid side chain attached via a linker, which promotes reversible binding to serum albumin.
- A further amino acid substitution that supports the acylation chemistry.
Together these modifications substantially extend circulating half-life relative to native GLP-1. Albumin binding in particular acts as a circulating reservoir, slowing clearance.
Mechanisms studied in research
The GLP-1 receptor is well characterised, and research using agonists spans several areas:
- Islet cell signalling. Glucose-dependent insulin secretion is the canonical mechanism, studied extensively in isolated islet and cell-line systems.
- Gastric motility models. Effects on gastric emptying rate have been examined in animal models.
- Central nervous system receptor expression. GLP-1 receptors in hypothalamic and brainstem regions have been mapped and studied in relation to feeding behaviour in rodent models.
- Receptor pharmacology. Binding affinity, receptor internalisation, and biased signalling are active areas of in vitro investigation across the GLP-1 agonist class.
Regulatory context
GLP-1 receptor agonists as a class include approved pharmaceutical products, and this is an important distinction for anyone working with research-grade material. Research-grade peptide supplied for laboratory use is not a pharmaceutical product, is not manufactured under the regulatory framework governing approved medicines, and is not intended for human use in any form. It is supplied for in vitro and preclinical investigation by qualified researchers.
Researchers should also be aware that this compound class has attracted significant regulatory attention. Institutional review and compliance requirements should be confirmed before beginning work.
Handling and storage in the laboratory
- Store the lyophilized vial refrigerated at 2 to 8 degrees Celsius; use minus 20 degrees Celsius or lower for extended storage.
- Reconstitute gently with bacteriostatic water; avoid vigorous agitation.
- Protect solutions from light and avoid repeated freeze-thaw cycles.
- Verify the certificate of analysis for the specific lot before use — for a modified peptide of this complexity, mass spectrometry confirmation of the expected molecular weight is particularly important, since the acylation and substitutions all affect the observed mass.
Research use only. This content is for educational and informational purposes related to scientific research. It is not medical advice and does not describe dosing or administration for human use. Products are sold for laboratory research by qualified professionals only.